

Finally, we have examined the chloroform extractive of the lichen thalli after the ether extraction and have isolated two neutral substances. The one obtained in a 0.1% yield was found identical with zeorin (V),<sup>8)</sup> while the more polar compound (0.15%) was identified with ergosterol peroxide (VI)<sup>9)</sup> which was prepared by photosensitized oxygenation of ergosterol.<sup>10)</sup>

**Acknowledgement** The authors wish to express their sincere thankness to Emeritus Professor Y. Asahina and Dr. M. Nuno for identification of the lichen material.

Kyoto College of Pharmacy,  
Yamashina-misasagi,  
Higashiyama-ku, Kyoto

Faculty of Pharmaceutical Sciences,  
Osaka University,  
133-1, Yamada-kami, Suita, Osaka, 565, Japan

TERUHISA HIRAYAMA  
FUKUJIRO FUJIKAWA

ITIRO YOSIOKA  
ISAO KITAGAWA

Received December 11, 1974

- 8) I. Yosioka, T. Nakanishi, H. Yamauchi, and I. Kitagawa, *Chem. Pharm. Bull.* (Tokyo), **20**, 147 (1972).  
9) R. Takahashi, O. Tanaka, and S. Shibata, *Phytochemistry*, **11**, 1850 (1972).  
10) A. Windaus and J. Brunken, *Liebig's Ann.*, **460**, 225 (1923).

[*Chem. Pharm. Bull.*  
**23**(3) 695-697 (1975)]

UDC 547.92.04 : 615.356.011.5

### Synthesis of Active Forms of Vitamin D. VIII.<sup>1)</sup> Synthesis of [24*R*]- and [24*S*]-1 $\alpha$ ,24,25-Trihydroxyvitamin D<sub>3</sub><sup>2)</sup>

24 $\xi$ ,25-Dihydroxycholesterol was converted, through 1,4,6-trien-3-one and its 1 $\alpha$ ,2 $\alpha$ -epoxide, into 1 $\alpha$ ,24 $\xi$ ,25-trihydroxycholesterol. After resolution of C-24 epimers and determining their configurations, both isomers were led to [24*R*]- and [24*S*]-1 $\alpha$ ,24,25-trihydroxyvitamin D<sub>3</sub> by bromination, dehydrobromination and ultraviolet-irradiation.


Vitamin D<sub>3</sub> is first hydroxylated in the liver on C-25 before it travels to the kidney to be hydroxylated either on C-1 or C-24.<sup>3)</sup> Under normal or hypercalcemic conditions the major circulating metabolite of 25-hydroxyvitamin D<sub>3</sub> is 24,25-dihydroxyvitamin D<sub>3</sub>.<sup>4)</sup> A polar metabolite of the latter has recently isolated by Holick, *et al.*<sup>5)</sup> and identified as 1,24,25-trihydroxyvitamin D<sub>3</sub>, although the stereochemistry at C-1 and C-24 has been remained to be determined. They have also reported that this vitamin D analog appears to have preferential action on the intestine.

In our continuing efforts of synthesis of vitamin D analogs having useful specific and/or enhanced activities and also in the hope of determining the absolute configurations of the natural 1,24,25-trihydroxyvitamin D<sub>3</sub>,<sup>5)</sup> we have now synthesized [24*R*]- and [24*S*]-1 $\alpha$ ,24,25-trihydroxyvitamin D<sub>3</sub> (**11** and **12**).

- 1) Part VII: N. Ikekawa, M. Morisaki, N. Koizumi, M. Sawamura, Y. Tanaka, and H.F. DeLuca, *Biochem. Biophys. Res. Comm.*, **62**, 485 (1975). This is also Part XVIII in the series of "Studies on Steroids," Part XVII: M. Nakane, M. Morisaki, and N. Ikekawa, *Tetrahedron*, in press.  
2) Presented at Fourth International Congress on Hormonal Steroids, Mexico City, September 3, 1974.  
3) H.F. DeLuca, *The American J. of Medicine*, **57**, 1 (1974).  
4) I.T. Boyle, J.L. Omdahl, R.W. Gray, and H.F. DeLuca, *J. Biol. Chem.*, **248**, 4174 (1973).  
5) M.F. Holick, A. K-Bossaller, H.K. Schnoes, P.M. Kasten, I.T. Boyle, and H.F. DeLuca, *J. Biol. Chem.*, **248**, 6691 (1973).

24 $\xi$ ,25-Dihydroxycholesterol **1**, mp 184—187° (AcOEt) derived from its 3-acetate<sup>6)</sup> was subjected to the procedures of Barton, *et al.*,<sup>7)</sup> to introduce 1 $\alpha$ -hydroxy function. Oxidation of **1** with DDQ/dioxane (reflux, 21 hr) gave trienone **2**, mp 193—197° (acetone) in 65% yield. By reaction of **2** with 30% H<sub>2</sub>O<sub>2</sub>/NaOH-MeOH, 1 $\alpha$ ,2 $\alpha$ -epoxide **3** was obtained in 76% yield; **3**, mp 164—166° (ether), M<sup>+</sup> 428.2900 (Calcd. 428.2926). Epoxide **3** was reduced with a large excess of Li in liquid ammonia-THF, followed by treatment with NH<sub>4</sub>Cl, affording 1 $\alpha$ ,24 $\xi$ ,25-trihydroxycholesterol (**4**) in 55% yield; **4**, mp 198—201° (acetone), NMR (C<sub>5</sub>D<sub>5</sub>N),  $\delta$  0.81 (3H, s, 18-Me), 1.07 (3H, s, 19-Me), 1.38 (6H, s, 26,27-Me), 3.47 (1H, m, C-24-H), 4.01 (1H, m, C-1-H), 4.50 (1H, m, C-3-H) and 5.50 ppm (1H, m, C-6-H).

At this stage, resolution of C-24 epimers was performed with dibenzoate trimethylsilyl ether **5** and dibenzoate acetate **6**, by means of silica gel column or thin-layer chromatography. Nuclear magnetic resonance (NMR) spectra of the less polar isomers **5a** and **6a** showed 18-methyl signals at the considerably lower field than those of the more polar ones **5b** and **6b** (see Table I). Comparable behaviors have been observed with 1 $\alpha$ -dehydroxy analogs **7** and **8**, whose configurations at C-24 were firmly established.<sup>8)</sup> It can be concluded from the data



TMS=tetramethylsilyl  
BZ=benzoyl

6) M. Seki, J. Rubio-Lightbourn, M. Morisaki, and N. Ikekawa, *Chem. Pharm. Bull.* (Tokyo), **21**, 2783 (1973).  
7) D.H.R. Barton, R.H. Hesse, M.M. Pechet, and E. Rizzardo, *J. Am. Chem. Soc.*, **95**, 2748 (1973).  
8) M. Seki, N. Koizumi, M. Morisaki, and N. Ikekawa, *Tetrahedron Letters*, **1975**, 15.

TABLE I. Chemical Shifts of C-18 Methyl (ppm)

Less polar compd.	18-CH <sub>3</sub>	More polar compd.	18-CH <sub>3</sub>
<b>5a</b>	0.68	<b>5b</b>	0.62
<b>6a</b>	0.66	<b>6b</b>	0.60
<b>7a</b> (24 <i>R</i> )	0.65	<b>7b</b> (24 <i>S</i> )	0.60
<b>8a</b> (24 <i>R</i> )	0.68	<b>8b</b> (24 <i>S</i> )	0.63

of Table I, that the more polar compounds should have [24*S*] and the less polar ones, [24*R*] configuration.

Bromination of **5a** with dibromodimethylhydantoin in hexane (reflux, 15 min) and dehydrobromination of the crude product with *s*-collidine in *p*-xylene (140°, 15 min) gave a mixture of dienes. This was saponified and purified with column chromatography on silica gel and then with AgNO<sub>3</sub>-impregnated thin-layer chromatography (TLC) to afford [24*R*]-5,7-diene **9** mp 191–193°  $\lambda_{\max}$  (EtOH), 272, 282 and 294 nm,  $m/e$  M<sup>+</sup> 432, NMR (deuterioacetone),  $\delta$  0.67 (3H, s, 18-Me), 0.91 (3H, s, 19-Me), 1.12 (6H, s, 26,27-Me), 3.32 (1H, m, C-24-H), 3.80 (1H, m, C-1-H), 4.08 (1H, m, C-3-H) and 5.52 ppm (2H, ABq,  $J=6$  Hz, C-6,7-Hs).

Irradiation of **9** was carried out with a 200 W medium pressure mercury lamp (Hanovia 654A 36) in ether–EtOH (1:1) solution (5°, 60 sec). The subsequent refluxing with benzene–EtOH to effect thermal isomerization and the purification with AgNO<sub>3</sub>-impregnated TLC afforded [24*R*]-1 $\alpha$ ,24,25-trihydroxyvitamin D<sub>3</sub> (**11**),  $\lambda_{\min}$  228 nm,  $\lambda_{\max}$  265 nm, NMR (deuterioacetone),  $\delta$  0.58 (3H, s, 18-Me), 1.12 (6H, s, 26,27-Me), 3.25 (1H, m, C-24-H), 4.15 (1H, m, C-1-H), 4.39 (1H, m, C-3-H), 5.30 and 4.93 (2H, two s, 19-CH<sub>2</sub>), and 6.18 ppm (2H, BAq,  $J=11$  Hz, C-6,7-Hs). Mass spectrum indicated prominent peaks at  $m/e$  432 (M<sup>+</sup>), 414, 396, 287, 269, 251 and 134 which are in good agreement with those of the metabolic product.<sup>5)</sup> Essentially by the same methods, [24*S*]-TMS ether **5b** was converted through 5,7-diene **10** mp 148–154° into [24*S*]-1 $\alpha$ ,24,25-trihydroxyvitamin D<sub>3</sub> (**12**). The spectral (UV, mass and NMR) properties of **12** were indistinguishable from those of [24*R*]-isomer **11**.

Biological activity of **11** and **12**, and their identification with the metabolic product<sup>5)</sup> are under investigation.

This work was supported by a grant from the Ministry of Education, for which we greatly appreciate.

Laboratory of Chemistry for Natural  
Products,  
Tokyo Institute of Technology,  
Ohokayama, Meguro-ku, Tokyo  
  
Teijin Institute for  
Biomedical Research,  
Hino-shi, Tokyo

NOBUO IKEKAWA  
MASUO MORISAKI  
NAOYUKI KOIZUMI  
  
YOSHINORI KATO  
TORU TAKESHITA

Received December 17, 1974

1) S. Honma and T. Nambara, *Chem. Pharm. Bull.* (Tokyo), **22**, 687 (1974); T. Nambara, J. Ishiguro, Y. Kwarada, and H. Tajima, *ibid.*, **22**, 889 (1974).